Proliferative Vitreoretinopathie: therapeutische Strategien

F. Schaub; P. Enders; S. Fauser

doi:10.1055/s-0042-107947

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2016; 233(09): 1016-1023
DOI: 10.1055/s-0042-107947

Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Proliferative Vitreoretinopathie: therapeutische Strategien

Proliferative Vitreoretinopathy: Therapeutic Strategies

Authors

F. Schaub^*

Zentrum für Augenheilkunde, Universität zu Köln
P. Enders^*

Zentrum für Augenheilkunde, Universität zu Köln
S. Fauser

Zentrum für Augenheilkunde, Universität zu Köln

Abstract

Zusammenfassung

Hintergrund: Die Entwicklung einer proliferativen Vitreoretinopathie (PVR) zählt zu den bedeutendsten Komplikationen vitreoretinaler Chirurgie und stellt die Retinologen bei der Indikationsstellung zur Behandlung und der operativen Versorgung oftmals vor eine Herausforderung. Material und Methoden: Eine Literaturübersicht aus PubMed sowie eigene Daten und Erfahrungen werden zusammengefasst. Ergebnisse: Bei den pharmakologischen Ansätzen zur Prävention und Therapie der proliferativen Vitreoretinopathie handelt es sich bisher lediglich um Konzepte, die im Rahmen präklinischer und weniger klinischer Studien untersucht wurden. Hier sind besonders antiinflammatorische und antiproliferative Substanzen zu erwähnen. Bei den chirurgischen Techniken reicht das operative Spektrum von der Buckelchirurgie bis hin zum Goldstandard der Pars-plana-Vitrektomie mit vorzugsweise Silikonölendotamponade. Das zusätzliche Anlegen einer Cerclage, einer Retinotomie oder Retinektomie kann helfen, die durch Traktion verkürzte Netzhaut zu entspannen und zur Anlage zu bringen. Schlussfolgerung: Die chirurgische Therapie stellt nach wie vor den wichtigsten Ansatzpunkt zur Behandlung der PVR dar. Eine medikamentöse Behandlungsstrategie zur Vermeidung oder Behandlung der PVR konnte bislang noch nicht etabliert werden.

Abstract

Background: Development of proliferative vitreoretinopathy (PVR) is one of the most important complications of vitreoretinal surgery. Reaching the decision to treat and surgical treatment itself are both challenging. Materials and Methods: Our own data and a review of the literature in PubMed are summarised. Results: Pharmacological approaches to the prevention and treatment of proliferative vitreoretinopathy have been limited to concepts that have been investigated in preclinical and a few clinical studies. Anti-inflammatory and antiproliferative substances may be mentioned in this context. Surgical techniques range from scleral buckling to the gold standard pars plana vitrectomy, preferably with silicone oil endotamponade. Applying an encircling band, retinotomy or retinectomy can be useful in reattaching the tractional shortened retina. Conclusion: Surgery is still the method of choice for the treatment of PVR. Pharmacological strategies to prevent or treat PVR have not been established.

Schlüsselwörter

proliferative Vitreoretinopathie - traktive Amotio - Silikonöl - Retinotomie - Komplikation

Key words

proliferative vitreoretinopathy - tractive retinal detachment - silicone oil - retinotomy - complication

Full Text

References

Literatur
1 Iandiev I, Bringmann A, Wiedemann P. [Proliferative vitreoretinopathy–pathogenesis and therapy]. Klin Monatsbl Augenheilkd 2010; 227: 168-174
2 Pastor JC, Fernández I, Coco RM et al. Variations in functional and anatomical outcomes and in proliferative vitreoretinopathy rate along a prospective collaborative study on primary rhegmatogenous retinal detachments: the Retina 1 Project-Report 4. ISRN Ophthalmol 2012; 2012: 206385
3 Pastor JC, Rojas J, Pastor-Idoate S et al. Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res 2016; 51: 125-155
4 Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update. Retina 2015; 35: 165-175
5 Kobayashi S, Sato S, Inoue M et al. Comparison of 20- and 25-gauge vitrectomy for primary repair of rhegmatogenous retinal detachment. Ophthalmic Surg Lasers Imaging 2010; 41: 550-554
6 Narayanan R, Sinha A, Reddy RK et al. Faster visual recovery after 23-gauge vitrectomy compared with 20-gauge vitrectomy. Retina 2010; 30: 1511-1514
7 Stalmans P. 23-gauge vitrectomy. Dev Ophthalmol 2014; 54: 38-44
8 Priglinger CS, Priglinger S. [Pharmacological approach to treatment of proliferative vitreoretinopathy]. Ophthalmologe 2013; 110: 948-959
9 Falkenstein IA, Cheng L, Wong-Staal F et al. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res 2008; 33: 599-609
10 Turgut B, Uyar F, Ustundag B et al. The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy. Retina 2012; 32: 232-241
11 Eibl KH, Lewis GP, Betts K et al. The effect of alkylphosphocholines on intraretinal proliferation initiated by experimental retinal detachment. Invest Ophthalmol Vis Sci 2007; 48: 1305-1311
12 Tahara YR, Sakamoto TR, Oshima YR et al. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy. Curr Eye Res 1999; 19: 323-329
13 Wu PC, Tai MH, Hu DN et al. Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells. J Ocul Pharmacol Ther 2008; 24: 25-33
14 Oshima Y, Sakamoto T, Hisatomi T et al. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy. Gene Ther 2002; 9: 1214-1220
15 Saika S, Yamanaka O, Ikeda K et al. Inhibition of p 38MAP kinase suppresses fibrotic reaction of retinal pigment epithelial cells. Lab Invest 2005; 85: 838-850
16 Lei H, Velez G, Cui J et al. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol 2010; 177: 132-140
17 Velez G, Weingarden AR, Lei H et al. SU9518 inhibits proliferative vitreoretinopathy in fibroblast and genetically modified Muller cell-induced rabbit models. Invest Ophthalmol Vis Sci 2013; 54: 1392-1397
18 Nassar K, Luke J, Luke M et al. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefes Arch Clin Exp Ophthalmol 2011; 249: 1649-1660
19 Pennock S, Rheaume MA, Mukai S et al. A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. Am J Pathol 2011; 179: 2931-2940
20 Liang CM, Tai MC, Chang YH et al. Glucosamine inhibits epithelial-to-mesenchymal transition and migration of retinal pigment epithelium cells in culture and morphologic changes in a mouse model of proliferative vitreoretinopathy. Acta Ophthalmol 2011; 89: e505-e514
21 Yang CH, Huang TF, Liu KR et al. Inhibition of retinal pigment epithelial cell-induced tractional retinal detachment by disintegrins, a group of Arg-Gly-Asp-containing peptides from viper venom. Invest Ophthalmol Vis Sci 1996; 37: 843-854
22 Zahn G, Volk K, Lewis GP et al. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. Invest Ophthalmol Vis Sci 2010; 51: 1028-1035
23 Ahmadieh H, Feghhi M, Tabatabaei H et al. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology 2008; 115: 1938-1943
24 Chen W, Chen H, Hou P et al. Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy. Retina 2011; 31: 1137-1142
25 Asaria RH, Kon CH, Bunce C et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001; 108: 1179-1183
26 Charteris DG, Aylward GW, Wong D et al. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004; 111: 2240-2245
27 Sundaram V, Barsam A, Virgili G. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev 2013; (1) CD006421
28 Wickham L, Bunce C, Wong D et al. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 2007; 114: 698-704
29 Wiedemann P, Hilgers RD, Bauer P et al. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 1998; 126: 550-559
30 Chang YC, Hu DN, Wu WC. Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. Am J Ophthalmol 2008; 146: 440-446
31 Fekrat S, de Juan jr. E, Campochiaro PA. The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy. Ophthalmology 1995; 102: 412-418
32 Berman DH, Gombos GM. Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans. Ophthalmic Surg 1989; 20: 268-272
33 Schiff WM, Hwang JC, Ober MD et al. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol 2007; 125: 1161-1167
34 Hoerster R, Hermann MM, Rosentreter A et al. Profibrotic cytokines in aqueous humour correlate with aqueous flare in patients with rhegmatogenous retinal detachment. Br J Ophthalmol 2013; 97: 450-453
35 Schroder S, Muether PS, Caramoy A et al. Anterior chamber aqueous flare is a strong predictor for proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. Retina 2012; 32: 38-42
36 Yu J, Peng R, Chen H et al. Elucidation of the pathogenic mechanism of rhegmatogenous retinal detachment with proliferative vitreoretinopathy by proteomic analysis. Invest Ophthalmol Vis Sci 2012; 53: 8146-8153
37 Dehghan MH, Ahmadieh H, Soheilian M et al. Effect of oral prednisolone on visual outcomes and complications after scleral buckling. Eur J Ophthalmol 2010; 20: 419-423
38 Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84: 1064-1067
39 Koerner F, Koerner-Stiefbold U, Garweg JG. Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial. Graefes Arch Clin Exp Ophthalmol 2012; 250: 981-987
40 Yamakiri K, Sakamoto T, Noda Y et al. One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 959-966
41 Araiz JJ, Refojo MF, Arroyo MH et al. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1993; 34: 522-530
42 Takahashi M, Refojo MF, Nakagawa M et al. Antiproliferative effect of retinoic acid in 1 % sodium hyaluronate in an animal model of PVR. Curr Eye Res 1997; 16: 703-709
43 Veloso jr. AA, Kadrmas EF, Larrosa JM et al. 13-cis-retinoic acid in silicone-fluorosilicone copolymer oil in a rabbit model of proliferative vitreoretinopathy. Exp Eye Res 1997; 65: 425-434
44 Kumar A, Nainiwal S, Choudhary I et al. Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery. Clin Experiment Ophthalmol 2002; 30: 348-351
45 Wiedemann P, Lemmen K, Schmiedl R et al. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol 1987; 104: 10-14
46 Wiedemann P, Leinung C, Hilgers RD et al. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1991; 229: 150-152
47 Iverson DA, Katsura H, Hartzer MK et al. Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy. Arch Ophthalmol 1991; 109: 405-409
48 Blumenkranz MS, Hartzer MK, Iverson D. An overview of potential applications of heparin in vitreoretinal surgery. Retina 1992; 12 (Suppl. 03) S71-S74
49 Blumenkranz M, Hernandez E, Ophir A et al. 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 1984; 91: 122-130
50 Kumar A, Nainiwal S, Sreenivas B. Intravitreal low molecular weight heparin in PVR surgery. Indian J Ophthalmol 2003; 51: 67-70
51 Scheer S, Morel C, Poisson F et al. [Prevention of proliferative vitreoretinopathy using 5-FU heparin: clinical tolerance and efficacy]. J Fr Ophthalmol 2005; 28: 701-706
52 Pastor JC, De La Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 2002; 21: 127-144
53 Sadaka A, Giuliari GP. Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol 2012; 6: 1325-1333
54 Coffee RE, Jiang L, Rahman SA. Proliferative vitreoretinopathy: advances in surgical management. Int Ophthalmol Clin 2014; 54: 91-109
55 Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 1998; 43: 3-18
56 Yao Y, Jiang L, Wang ZJ et al. Scleral buckling procedures for longstanding or chronic rhegmatogenous retinal detachment with subretinal proliferation. Ophthalmology 2006; 113: 821-825
57 Adelman RA, Parnes AJ, Sipperley JO et al. Strategy for the management of complex retinal detachments: the European vitreo-retinal society retinal detachment study report 2. Ophthalmology 2013; 120: 1809-1813
58 Storey P, Alshareef R, Khuthaila M et al. Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy. Retina 2014; 34: 1945-1951
59 Erakgun T, Egrilmez S. Surgical outcomes of transconjunctival sutureless 23-gauge vitrectomy with silicone oil injection. Indian J Ophthalmol 2009; 57: 105-109
60 Riemann CD, Miller DM, Foster RE et al. Outcomes of transconjunctival sutureless 25-gauge vitrectomy with silicone oil infusion. Retina 2007; 27: 296-303
61 Shah CP, Ho AC, Regillo CD et al. Short-term outcomes of 25-gauge vitrectomy with silicone oil for repair of complicated retinal detachment. Retina 2008; 28: 723-728
62 Iwahashi-Shima C, Sato T, Bando H et al. Anatomic and functional outcomes of 25-gauge vitrectomy for repair of eyes with rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy. Clin Ophthalmol 2013; 7: 2043-2049
63 Williamson TH, Gupta B. Planned delayed relaxing retinotomy for proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging 2010; 41: 31-34
64 Quiram PA, Gonzales CR, Hu W et al. Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Ophthalmology 2006; 113: 2041-2047
65 Tsui I, Schubert HD. Retinotomy and silicone oil for detachments complicated by anterior inferior proliferative vitreoretinopathy. Br J Ophthalmol 2009; 93: 1228-1233
66 Banaee T, Hosseini SM, Eslampoor A et al. Peripheral 360 degrees retinectomy in complex retinal detachment. Retina 2009; 29: 811-818
67 Minarcik JR, von Fricken MA. Virtual retinectomy: indocyanine green-assisted internal limiting membrane peeling as a surgical adjunct in repair of recurrent rhegmatogenous retinal detachment due to PVR. Clin Ophthalmol 2012; 6: 631-636
68 [Anonymous] Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol 1992; 110: 770-779
69 Auriol S, Pagot-Mathis V, Mahieu L et al. Efficacy and safety of heavy silicone oil Densiron 68 in the treatment of complicated retinal detachment with large inferior retinectomy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1383-1389
70 Li W, Zheng J, Zheng Q et al. Clinical complications of Densiron 68 intraocular tamponade for complicated retinal detachment. Eye (Lond) 2010; 24: 21-28
71 Rizzo S, Genovesi-Ebert F, Vento A et al. A new heavy silicone oil (HWS46–3000) used as a prolonged internal tamponade agent in complicated vitreoretinal surgery: a pilot study. Retina 2007; 27: 613-620
72 Boscia F, Furino C, Recchimurzo N et al. Oxane HD vs. silicone oil and scleral buckle in retinal detachment with proliferative vitreoretinopathy and inferior retinal breaks. Graefes Arch Clin Exp Ophthalmol 2008; 246: 943-948
73 Joussen AM, Rizzo S, Kirchhof B et al. Heavy silicone oil versus standard silicone oil in as vitreous tamponade in inferior PVR (HSO Study): interim analysis. Acta Ophthalmol 2011; 89: e483-e489
74 Mitry D, Awan MA, Borooah S et al. Surgical outcome and risk stratification for primary retinal detachment repair: results from the Scottish Retinal Detachment study. Br J Ophthalmol 2012; 96: 730-734
75 Regler R, Sachs HG, Hillenkamp J et al. [Long-term evaluation of anatomic and functional results after complicated retinal detachment treated with pars plana vitrectomy and heavy silicone oil tamponade]. Klin Monatsbl Augenheilkd 2009; 226: 707-712
76 Kiss CG, Richter-Muksch S, Sacu S et al. Anatomy and function of the macula after surgery for retinal detachment complicated by proliferative vitreoretinopathy. Am J Ophthalmol 2007; 144: 872-877
77 Diddie KR, Azen SP, Freeman HM et al. Anterior proliferative vitreoretinopathy in the silicone study. Silicone Study Report Number 10. Ophthalmology 1996; 103: 1092-1099
78 Hahn GH. Kurzlehrbuch Augenheilkunde. Stuttgart: Thieme; 2008
79 Kellner U, Wachtlin J. Retina. Diagnostik und Therapie von Erkrankungen des hinteren Augenabschnitts. Stuttgart: Thieme; 2008